FLU JUST MET
ITS GENETIC MATCH


Target influenza with Supemtek (Quadrivalent Influenza Vaccine, recombinant prepared in cell-culture), the first recombinant influenza vaccine in Europe. Supemtek is manufactured to offer an exact genetic match to the World Health Organization (WHO)-predicted viral strains haemagglutinin antigen.1,2

Supemtek quadrivalent influenza vaccine is indicated for active immunisation for the prevention of influenza disease in adults.1

Supemtek Prescribing Information



THE UNDERESTIMATED THREAT OF INFLUENZA

A recent self-controlled case series study showed that adults aged 40 years and older, without a history
of heart attack or stroke, were at an increased risk of severe cardiovascular complications in the 13 days following a confirmed influenza infection.3

Patients were at a 10x increased risk of a first heart attack and 8x increased risk of a first stroke.3

Each year in the UK, influenza vaccination could help to reduce the number of influenza cases and influenza-related premature deaths.4


INTRODUCING SUPEMTEK


RECOMBINANT TECHNOLOGY

Recombinant technology eliminates the possibility of adaptation or mutation during the manufacturing process by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain.2,5

FIND OUT MORE ABOUT THE RECOMBINANT TECHNOLOGY USED TO MANUFACTURE SUPEMTEK HERE

 

INCREASED HA CONTENT

Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain compared with cell- and egg-based standard-dose quadrivalent influenza vaccine.2


 

PROVEN EFFICACY

Supemtek demonstrated 30% greater relative efficacy (1% absolute efficacy) versus standard-dose egg-based quadrivalent inactivated influenza vaccine (QIVe), in preventing confirmed cases of influenza-like illness in adults aged 50+ years, with respective influenza attack rates of 2.2% and 3.2 %.*2

FIND OUT MORE ABOUT THE CLINICAL DATA FOR SUPEMTEK HERE

 

COMPARABLE SAFETY PROFILE

Supemtek demonstrated a comparable safety profile to standard-dose egg-based QIVe.2,6


 

SUPPORTED BY RANDOMISED CONTROLLED TRIALS

Randomised controlled trials support the efficacy and safety of Supemtek for active immunisation for the prevention of influenza disease in adults aged 18+ years.2,6


*As measured by relative vaccine efficacy (rVE) in adults aged 50+ years, randomised 1:1 to receive single dose of Supemtek (n=4303) or standard-dose egg-based QIVe (n=4,301) during the 2014/15 influenza season (95% CI 10–47; P=0.006). Influenza attack rates were 2.2.% and 3.2% for Supemtek and standard-dose QIVe, respectively. The lower bound (LB) of the 95% confidence interval met the pre-specified, exploratory criterion for superior rVE LB >9%. Primary endpoint: rVE against reverse transcription polymerase chain reaction-confirmed, protocol-defined, influenza-like illness caused by an influenza strain starting 14 days or more after vaccination.2

HA, haemagglutinin; LB, lower bound; QIVe, quadrivalent inactivated influenza vaccine;
rVE, relative vaccine efficacy; WHO, World Health Organization.


REFERENCES:

  1. Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) Summary of Product Characteristics. Sanofi Pasteur
    [November 2020].
  2. Dunkle LM, et al. N Engl J Med. 2017;376:2427–36.
  3. Warren-Gash C, et al. Eur Resp J. 2018;51:1701794.
  4. Franklin B and Hochlaf D. An economic analysis of flu vaccination. Available at: https://ilcuk.org.uk/wp-content/uploads/2018/07/An_economic_analysis_of_flu_vaccination_-_ILC-UK.pdf. [Last accessed October 2020].
  5. Centers for Disease Control and Prevention. How influenza (flu) vaccines are made. Available at: https://www.cdc.gov/flu/prevent/how-fluvaccine-made.htm#recombinant [Last accessed October 2020].
  6. Dunkle LM, et al. J Infect Dis. 2017;216:1219–26.



Reporting side effects
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively send via email to
UK-drugsafety@sanofi.com

 

Date of preparation: March 2021 | MAT-GB-2003349(v1.0)